Lifecore Biomedical (LFCR) announced its acquisition by Webster Equity Partners for up to $663.7 million, including a cash payment of $6.28 per share and contingent value rights (CVRs). This transaction represents a significant premium for shareholders and aims to support Lifecore's growth objectives, leading to its delisting from Nasdaq.
Lifecore Biomedical (LFCR) is being acquired by Webster Equity Partners in a deal valued at up to $663.7 million. This is a major corporate catalyst for LFCR shareholders, who will receive an immediate cash payment of $6.28 per share, representing a 49.5% premium, plus CVRs that could bring the total value to $9.67 per common equivalent if performance milestones are met. The acquisition provides an immediate and compelling value proposition for existing shareholders, while Webster Equity Partners aims to leverage Lifecore's CDMO expertise for future growth. Short-term, LFCR stock is likely to trade near the cash offer price, with potential upside tied to CVR expectations. Long-term, LFCR will cease to be a publicly traded company. A key risk for traders is the non-tradable nature of the CVRs and the uncertainty of achieving full performance milestones.